Teduglutide for treatment of adult patients with short bowel syndrome

Introduction: The European Society for Clinical Nutrition has published recommendations on the definition and classification of intestinal failure (IF)'. Two criteria must be present: a decreased absorption of macronutrients and/or water and electrolytes due to a loss of gut function' and the need for parenteral support'. Home parenteral support (HPS) is the primary treatment for chronic IF but is associated with complications.Areas covered: The principal cause of chronic IF is short bowel syndrome (SBS). The aim of treatment is to maximize intestinal absorption and reduce or eliminate the need for HPS to achieve the best possible quality of life. Teduglutide, an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth, reducing intestinal loss and promoting intestinal absorption. This article provides an overview and opinion on teduglutide for SBS.Expert opinion: Teduglutide may provide a new treatment strategy for SBS patients with chronic IF. When prescribed, patients should be informed of the benefits and risks of the drug and must be closely monitored in an expert center. Furthermore, as this treatment is costly, cost-effectiveness analysis as well as the risk-benefit ratio needs to be better evaluated.